Monitoring Monoclonal Gammopathies
International Myeloma Working Group: Disease Monitoring
November 2009
The International Myeloma Working Group has recommended using serum and urine M-spikes, if they are sufficiently large to allow assessment of response. This slide shows the definition of a measurable M-spike, that is >1 g/dL in serum, and >200 mg/24 hour in urine.
Disease Monitoring |
Jump to section:
- Introduction
- Slide Images
- International Myeloma Working Group: Disease Monitoring
- Serum Protein Electrophoresis and Immunofixation Electrophoresis
- Serum and Urine Protein Electrophoresis and Immunofixation Electrophoresis
- Methods for Monitoring Monoclonal Gammopathies: 2005 IMWG
- Methods for Monitoring Monoclonal Gammopathies
- Small IgG kappa M-spike
- Large IgG kappa M-spike
- Relationship of Serum Agarose Electrophoresis M-spike and Ig Quantitation1
- Disease Monitoring
- Monoclonal Gammopathies: Primary Systemic Amyloidosis
- Free Light Chain: Antibody Specificity
- FLC κ/λ Ratio: Disease Sensitivity2
- Methods for Monitoring Monoclonal Gammopathies
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring3
- Response Criteria for FLC4,5
- Receiver Operator Curve (ROC): % FLC Reduction vs. Overall Hematologic Response6
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document